ScoreWhy is Xilio Therapeutics, Inc. ?
1
With a growth in Net Sales of 331.67%, the company declared Very Positive results in Mar 26
- The company has declared positive results for the last 9 consecutive quarters
- NET SALES(Q) At USD 12.65 MM has Grown at 331.67%
- NET PROFIT(HY) Higher at USD -23.74 MM
- ROCE(HY) Highest at -75.2%
2
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of -4.96%, its profits have risen by 28.7%
3
Reducing Promoter Confidence
- Promoters have decreased their stake in the company by -18.43% over the previous quarter and currently hold 34% of the company
- Promoters decreasing their stake may signify reduced confidence in the future of the business
4
Consistent Underperformance against the benchmark over the last 3 years
- Along with generating -4.96% returns in the last 1 year, the stock has also underperformed S&P 500 in each of the last 3 annual periods
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Xilio Therapeutics, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Xilio Therapeutics, Inc. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Xilio Therapeutics, Inc.
-4.96%
0.51
1419.58%
S&P 500
25.41%
1.92
13.25%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
113.89%
EBIT Growth (5y)
4.24%
EBIT to Interest (avg)
-64.55
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-8.21
Sales to Capital Employed (avg)
-0.04
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
62.34%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.36
EV to EBIT
2.10
EV to EBITDA
2.18
EV to Capital Employed
0.87
EV to Sales
-2.01
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
41.60%
ROE (Latest)
-115.90%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bullish
Mildly Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend18What is working for the Company
NET SALES(Q)
At USD 12.65 MM has Grown at 331.67%
NET PROFIT(HY)
Higher at USD -23.74 MM
ROCE(HY)
Highest at -75.2%
RAW MATERIAL COST(Y)
Fallen by -17.36% (YoY
-2What is not working for the Company
OPERATING CASH FLOW(Y)
Lowest at USD -56.32 MM
Here's what is working for Xilio Therapeutics, Inc.
Net Sales
At USD 12.65 MM has Grown at 331.67%
Year on Year (YoY)MOJO Watch
Near term sales trend is extremely positive
Net Sales (USD MM)
Net Profit
Higher at USD -23.74 MM
than preceding 12 month period ended Mar 2026MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months
Net Profit (USD MM)
Raw Material Cost
Fallen by -17.36% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Xilio Therapeutics, Inc.
Operating Cash Flow
Lowest at USD -56.32 MM
in the last three yearsMOJO Watch
The company's cash revenues from business operations are falling
Operating Cash Flows (USD MM)
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
